

# Lydia L. Benitez, PharmD, BCOP

1540 East Medical Drive, CW7 Room 251B

Ann Arbor, MI 48109

787-630-6458 lbenitez@med.umich.edu

## Education and ASHP Accredited Post-Graduate Training

---

<b>Post Graduate Year Two Hematology/Oncology Pharmacy Residency</b> <i>University of Michigan Health System, Ann Arbor, MI</i> <i>Residency Director: Shawna Kraft, PharmD, BCOP</i>	Jul 2015-Jun 2016
<b>Post Graduate Year One Pharmacy Practice Residency</b> PGY1 Chief-Resident <i>University of Michigan Health System, Ann Arbor, MI</i> <i>Residency Director: John Clark, PharmD, MS, BCPS</i>	Jul 2014-Jun 2015
<b>Doctor of Pharmacy</b> Graduated with High Distinction <i>University of Michigan College of Pharmacy, Ann Arbor, MI</i>	Sep 2010-Apr 2014
<b>Bachelor of Science – Biology</b> <i>University of Michigan College of Literature, Science &amp; the Arts, Ann Arbor, MI</i>	Sep 2005-Dec 2009

## Professional Experience

---

<b>Adult Outpatient Leukemia Pharmacist Specialist –</b> <i>Michigan Medicine, University of Michigan, Ann Arbor, MI</i> <i>Supervisor: Rachel McDevitt, PharmD, BCOP (interim)</i>	Aug 2018-Present
<b>Hematology/Oncology Clinical Specialist –</b> <b>Inpatient/Outpatient Malignant Hematology and Hematopoietic Cell Transplant</b> <i>University of Kentucky Healthcare, Lexington, KY</i> <i>Supervisor: Amber Lawson, PharmD, BCOP</i>	Aug 2016-Jul 2018
<b>Cancer Center Infusion Pharmacy Staff Pharmacist</b> <i>University of Michigan Cancer Center, Ann Arbor, MI</i> <i>Supervisor: Kelly Procailo, PharmD</i>	Jul 2015-Jun 2016
<b>Inpatient Clinical and Staff Pharmacist –</b> <b>Pharmacokinetic, Anticoagulation, Nutrition, and Staffing</b> <i>Michigan Medicine, Ann Arbor, MI</i> <i>Supervisor: Pamela Walker, PharmD, BCPS &amp; Kathy Kinsey, RPh</i>	Jul 2014-Jun 2016

## Academic Appointments

---

<b>Clinical Assistant Professor</b> <i>University of Michigan College of Pharmacy, Ann Arbor, MI</i> <i>Supervisor: Manjunath (Amit) Pai, PharmD, FCP</i>	Jul 2020-Present
<b>Adjunct Clinical Pharmacy Instructor</b> <i>University of Michigan College of Pharmacy, Ann Arbor, MI</i>	Aug 2018-Jun 2020
<b>Adjunct Professor, Pharmacy Practice and Science</b> <i>University of Kentucky, Lexington, KY</i>	Feb 2017-Jul 2018

## Teaching and Precepting Experience

---

### Clinical Assistant Professor

Jul 2020 -Present

*University of Michigan College of Pharmacy, Ann Arbor, MI*

- Course Coordinator for Pharm 302 – Personal and Professional Development
- Course Co-Coordinator for Pharm 637 – Oncology Elective
- IPPE Ambulatory care rotation experience
- APPE Ambulatory care rotation experience
- PharmD Investigations project mentor
- P706 MUE preceptor

### Pharmacy Residency Preceptor

Aug 2018-Present

*Michigan Medicine, Ann Arbor, MI*

- Adult Leukemia ambulatory care experience
- Mentor for PGY1 writing projects, PGY1 and PGY2 research projects
- Member of the Executive Residency Advisory Committee (eRAC) since Aug 2019

### Adjunct Clinical Pharmacy Instructor

Aug 2018-Jun 2020

*University of Michigan College of Pharmacy, Ann Arbor, MI*

- IPPE Ambulatory care rotation experience
- APPE Ambulatory care rotation experience
- PharmD Investigations project mentor
- P706 MUE preceptor
- Lecturer in Course P718 – *Clinical pharmacogenomics in oncology*

### Adjunct Professor, Pharmacy Practice and Science

Feb 2017-Jul 2018

*University of Kentucky, Lexington, KY*

- PPS966 Oncology – Chemo induced nausea/ vomiting and Chronic Lymphocytic Leukemia
- PPS895 Oncology Elective – CAR-T cells in melanoma
- APPE Inpatient Malignant Hematology rotation experience

### Pharmacy Residency Preceptor

Feb 2017-Jul 2018

*University of Kentucky, Lexington, KY*

- Inpatient Malignant Hematology rotation experience
- Inpatient Hematopoietic Cell Transplant rotation experience
- Outpatient Hematology/Hematopoietic Cell Transplant rotation experience

## Peer-Reviewed Publications

---

Homan MJ, Reid JH, Nachar VR, **Benitez LL**, Brown AM, et al. Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. *Support Care Cancer*. 2021 Apr 27. doi: 10.1007/s00520-021-06239-0. Online ahead of print.

Perissinotti AJ, **Benitez LL**, Marini BL. Oral Azacitidine Maintenance for Acute Myeloid Leukemia. *N Engl J Med*. 2021 Apr 1;384(13):e51.

**Benitez LL [corresponding]**, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. *Leuk Lymphoma*. 2021: 021, AHEAD-OF-PRINT, 1-9.

Ravi K, Franson A, Homan MJ, Roberts H, Pai MP, Miklja Z, He M, Wen B, **Benitez LL**, et al. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. *Leuk Lymphoma*. 2021;7:1-6.

Reid J, Perissinotti AJ, **Benitez L**, et al. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for

---

acute leukemia with mixed-phenotype blasts. *Leuk Res*. 2021 Feb 19;103:106539.

Reid J, Marini B, **Benitez L**, Pettit K, Bixby D, et al. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. In press.

Ochs M, Perissinotti A, Marini B, Burke P,..., **Benitez L**[corresponding]. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. *Leuk Res*. 2021 Jan;102:106517.

Bazzell B, **Benitez L**, Marini B, Perissinotti A, Phillips T, et al. Evaluating the role of novel oncology agents: oncology stewardship in relapsed/refractory diffuse large b-cell lymphoma. *Clin Lymphoma Myeloma Leuk*. 2020 Dec;S2152-2650(20)31039-9.

Reid JH, Perissinotti AJ, **Benitez L**, Bixby DL, Burke P, et al. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. *Leuk Lymphoma*. 2020. 61(4):862-868.

Hickey E, Clemons B, Griffin S, Cox J, Sutphin S, Ramlal R, **Benitez L** [corresponding]. Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia. *Leuk Lymphoma*. 2019 Dec;60(14):3557-3560.

Marini BL, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, **Benitez LL** [corresponding]. Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? *Cancer*. 2019 Nov 1;125(21):3890-3891.

Alsawah F, **Benitez L**, Choi S, Marini B, Perissinotti A, et al. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. *Blood Adv*, 2019.Nov 12;3(21):3333-3336.

Marini B, Brown J, **Benitez L**, Walling E, Hutchinson RJ, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. *Leuk Lymphoma*, 2019. May 17:1-15.

Cheung E, Perissinotti AJ, Bixby DI, Burke PW, Pettit KM, **Benitez LL**, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. *Ann Hematol*, 2019.9893:541-559.

Ratermann K, Cox J, **Benitez L**, Davis F. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Ray SD. Side Effects of Drugs Annual. Vol.40. Massachusetts: Elsevier. 2018. Ch.36: 477-487.

Rausch CR, Marini BL, **Benitez L**, Elias A, Burke PW, et al. PEGing down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. *Leuk Lymphoma*, 2018. 59(3):617-624.

Tang L, Marini B, **Benitez L**, Nagel J, Berglund C, et al. Risk factors for subtherapeutic levels of posaconazole tablets. *Journal of Antimicrobial Chemotherapy*, 2017. 72(10):2902-2905.

Marini BL, **Benitez L**, Zureick AH, Salloum R, Gauthier AC, et al. Blood-brain-barrier-adapted precision medicine therapy for pediatric brain tumors. *Translational Research*, 2017. 188:27.e1-27.e14.

**Benitez L**, Gharibian K, Frame D, Mody R, Mora E. Clofarabine dosing in a patient with AML on intermittent hemodialysis: Case report and review of the literature. *JPHO*, 2017. 39(6):481-484.

Mackler E, Petersen L, Severson JA, Blayney D, **Benitez L**, et al. Implementing a method for evaluating patient reported outcomes associated with oral oncolytic therapy. *JOP*, 2017. 13(4):e395-e400.

Kaminsky B, **Benitez L**, Bostwick J, Early C, Klein K. Benefits of a concentrated teaching rotation: Perspectives of pharmacy residents and faculty. *Currents in Pharmacy Teaching and Learning*, 2017. 9(2017)4-8.

Koschmann C, Marini B, **Benitez Colon L**, Wu Y, Kumar C, et al. PDCT-03. Clinically integrated sequencing in the management of children with high-risk brain tumors. *Neuro-Oncology*, 2016. 18, Suppl.16

**Benitez L**, Perissinotti A, Santarossa M, Marini B. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. *Pediatr. Blood Cancer*, 2015. 62(6):1115.

## Poster and Professional Presentations (selected)

---

- Multicenter Comparison of Re-induction Regimens in Relapsed/Refractory Ph- ALL  
Madeleine A. Ochs, PharmD1 ; Brian G. Bazzell, PharmD1 ; Taylor M. Weis,  
PharmD, BCOP2 ; Sarah E. Stump, PharmD, BCOP2 ; Thomas Diaz3 ; Justin H Reid,  
PharmD, BCOP3 ; Kaitlyn M. Buhlinger, PharmD, BCOP3 ; Benyam Muluneh,  
PharmD, BCOP3 ; Lydia L. Benitez, PharmD, BCOP1 ; Bernard L. Marini, PharmD,  
BCOP1 ; Anthony J. Perissinotti, PharmD, BCOP1
- Clark KA, Marini BL, Perissinotti AJ, Benitez LL. Retrospective Evaluation of Opioid Use In  
the Inpatient Acute Leukemia Population. Poster. *Presented at 2021 Hematology  
Oncology Pharmacist Association Annual Meeting, Virtual.* Apr 2021
- Stonerock D, Homan M, Marini B, Perissinotti A, Bixby D, Pettit K, Burke P, **Benitez L**  
[primary investigator]. A single-center comparison of decitabine ± venetoclax or FLAG in  
the treatment of secondary AML. Abstract 387. *Presented at 2020 Society of Hematologic  
Oncology, Virtual.* Aug 2020
- Homan M, Perissinotti A, Marini B, Burke P, Bixby D, Pettit K, **Benitez L** [primary  
investigator]. Outcomes in Patients with Acute Myeloid Leukemia Receiving 10-day  
Decitabine with or without Venetoclax.  
*2020 Hematology/Oncology Pharmacy Association Annual Conference. Tampa, FL.* Mar 2020
- Evolving Therapies in Acute Myeloid Leukemia. ACPE accredited presentation.  
*Transplantation & Cellular Therapy Meetings, Pharmacist Conference.* Feb 2019  
*Houston, TX.*
- Cheung E, McKenzie MG, **Benitez Colon L**, Kaye KS, Petty L, et al. Impact of Standard  
versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated  
Staphylococcus aureus Bacteremia (SAB) in Patients with Hematologic Malignancies.  
*2018 ID Week. San Francisco, CA.* Oct 2018
- Corbett D, Adams V, **Benitez Colon L**, Cox J, Brignola M, et al. Anticoagulation in the  
setting of thrombocytopenia in cancer patients.  
*2018 Hematology/Oncology Pharmacy Association Annual Conference. Denver, Co.* Mar 2018
- Hickey E, Clemons B, Cox J, Sutphin S, **Benitez Colon L**. Evaluation of arsenic trioxide  
dosing in obese patients with acute promyelocytic leukemia.  
*2018 Hematology/ Oncology Pharmacy Association Annual Conference. Denver, Co.* Mar 2018
- Cheung E, McKenzie M, **Benitez Colon L**, Marini B, Perissinotti A, et al. Impact of standard  
versus prolonged courses of antibiotics for the treatment of uncomplicated  
staphylococcus aureus bloodstream infections in patients with hematologic malignancies.  
*2018 Hematology/ Oncology Pharmacy Association Annual Conference. Denver, Co.* Mar 2018
- Acute Myeloid Leukemia Updates. ACPE accredited presentation.  
*Tennessee Oncology Pharmacist Association Annual Meeting.* Sep 2017  
*Nashville, TN.*
- Oncologic Stewardship Pharmacy Grand Rounds Presentation Jun 2017  
*Markey Cancer Center pharmacy department presentation (ACPE accredited).*  
*UK Healthcare, Lexington, KY.*

<b>Benitez L, Patel T, Rao K, Nagel J.</b> Evaluation of pseudomonas outcomes stratified by carbapenem minimum inhibitory concentration. <i>2016 ASM Microbe Conference, Boston, MA.</i>	Jun 2016
Olanzapine for the Prevention of Emesis in Patients with Multiple Myeloma Receiving High-dose Melphalan Prior to Autologous Transplantation <i>Great Lakes Pharmacy Residency Conference (ACPE accredited). West Lafayette, IN.</i>	Apr 2016
Predicting CNS Penetration of Chemotherapeutics: Quite the Headache! <i>University of Michigan Health System (ACPE accredited), Ann Arbor, MI.</i>	Feb 2016
Evaluation of Pseudomonas Outcomes Stratified by Carbapenem Minimum Inhibitory Concentration <i>Great Lakes Pharmacy Residency Conference (ACPE accredited). West Lafayette, IN.</i>	Apr 2015
Adverse Effects of Antifungal Agents <i>University of Michigan Health System (ACPE accredited), Ann Arbor, MI.</i>	Feb 2015

## Leadership

<b>Cancer Pharmacy Committee Vice-Chair</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Dec 2020-Present
<b>Residency Advisory Committee</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Aug 2019-Present
<ul style="list-style-type: none"> <li>• Preceptor appointment workgroup member</li> <li>• Teaching certificate workgroup member</li> <li>• Resident and Preceptor award committee member</li> </ul>	
<b>Advanced Practice Practitioners Oncology Summit</b> - Member of planning committee	Aug 2020-Present
<b>Markey Pharmacy Resident and Learner Research Coordinator</b> <i>UKHealthcare, Lexington, KY</i>	Jan 2017-Jul 2018
<b>Cancer Pharmacy Committee Member</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Jul 2015-Jun 2016
<b>Research Series Coordinator</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Jul 2014-Jun 2016
<b>University of Michigan College of Pharmacy Liaison</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Jul 2014-Jun 2016
<b>Post-Graduate Year One Chief Resident</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Jul 2014-Jun 2015
<b>Residency Advisory Committee Member</b> <i>University of Michigan Health System, Ann Arbor, MI</i>	Jul 2014-Jun 2015

## Honors and Awards

University of Michigan Oncology Preceptor of the Year	Jun 2020
Michigan Medicine Making a Difference Award	Sep 2019
University of Kentucky APPE Preceptor of the Year Nominee	Jun 2018
UKHealthcare Pharmacy Department Rookie of the Year Award	Sep 2017
Julia E. Emanuel Award for community service, leadership, and academic performance	May 2014

The Honor Society of Phi Kappa Phi, University of Michigan	Dec 2013
Rho Chi Academic Honor Society, University of Michigan Alpha Chapter	Apr 2013
College of Pharmacy Academic High Distinction Dean Scholarship	2012- 2014
College of Pharmacy Academic Distinction Dean Scholarship	Sep 2011
University Honors for Scholastic Achievement	Dec 2009
Barbara J. Rotvig Scholastic Achievement and Sportsmanship Scholarship	May 2007-May 2008
University of Michigan Athletic Academic Achievement Award	May 2006-May 2009

## **Professional Activity and Membership**

---

American Hematology Society	Dec 2019 -Present
Phi Lambda Chi Curriculum Vitae Reviewer for University of Michigan pharmacy students	Sep 2017-Present
Hematology Oncology Pharmacists Association	Sep 2015-Present
Reviewer for: <i>Clinical Lymphoma, Myeloma, and Leukemia, Leuk. Lymphoma, Cancer</i>	Apr 2015 - Present
Hematology Oncology Pharmacist Association Abstract Reviewer Committee	Jun 2016-Jun 2017

## **Certifications and Licenses**

---

<b>Board of Pharmacy Specialties - Board Certified Oncology Pharmacist #5150688</b>	Jul 2017-Present
<b>Michigan Board of Pharmacy, Pharmacist License #5302040302</b>	Jul 2014-Present
<b>Michigan Board of Pharmacy, Controlled Substance License #5302040302</b>	Jul 2014-Present
<b>University of Michigan Health System &amp; College of Pharmacy Teaching Certificate</b>	Awarded Jul 2015
<b>APhA Pharmacy Based Immunization Delivery Certification</b>	Awarded Jun 2011

## **Languages**

---

Bilingual: Fluent in English and Spanish